On May 29, WuXi XDC rose 3.22% in regular trading, trading at HKD 53.35/share, with trading volume of HKD 33.98 million, rebounding after multiple consecutive sessions of decline.

On the news front, the company disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and May 29, representing approximately 0.45% of total issued shares, at a total cost of approximately HKD 327 million and an average purchase price of HKD 57.3 per share. All funds were sourced entirely from the company's own financial resources.

This execution follows WuXi XDC's earlier announcement of a share repurchase plan of up to USD 100 million using internal funds, while parent company WuXi Biologics also declared a separate USD 400 million buyback program, bringing the combined repurchase commitment across the WuXi group to USD 500 million. Guotai Haitong maintains an Outperform rating on the stock with a target price of HKD 84.38, citing strong ADC pipeline growth prospects. Within the Life Sciences Tools and Services sector, WuXi AppTec rose 4.06% and WuXi Biologics gained 1.85%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)